Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome
- PMID: 18337588
- PMCID: PMC2677974
- DOI: 10.1212/01.wnl.0000291011.54508.aa
Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome
Abstract
Objective: To determine if a relationship exists between the clinical features of Rett syndrome, an X-linked dominant neurodevelopmental disorder, and specific mutations in MECP2.
Method: Cross-sectional study of 245 girls and women with typical Rett syndrome seen between 1990 and 2004 in tertiary academic outpatient specialty clinics and who had complete MECP2 mutation analysis. A structured clinical evaluation was completed for each participant. The results were grouped by MECP2 mutation and compared.
Results: Participants with the R133C mutation are less severely affected than those with R168X or large DNA deletions (p < 0.05). Likewise, individuals with the R168X mutation are more severely affected than those with R294X and late carboxy-terminal truncating mutations (p < 0.05). Clinical differences are notable in ambulation, hand use, and language (p < 0.004), three cardinal features of Rett syndrome. Individuals with R168X are less likely to walk (p = 0.008), retain hand use (p = 0.002), or use words (p = 0.001). In contrast, those with carboxy-terminal truncations are more likely to walk (p = 0.007) and use words (p < 0.001). The R306C mutation, previously found to confer milder features, adversely affects only one clinical feature, language (p < 0.05).
Conclusions: Specific mutations in MECP2 confer different severity. These results allow the design of therapies targeted toward the amelioration of expected problems. Furthermore, the distinct effects of MECP2 mutations on clinical severity must be considered in clinical intervention trials.
Figures


Comment in
-
Will my Rett syndrome patient walk, talk, and use her hands?Neurology. 2008 Apr 15;70(16):1302-3. doi: 10.1212/01.wnl.0000309213.74757.74. Neurology. 2008. PMID: 18413585 No abstract available.
References
-
- Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, et al. Rett syndrome in Australia: a review of the epidemiology. J Pediatr. 2006;148(3):347–352. - PubMed
-
- Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist. 2004;10(2):118–128. - PubMed
-
- Glaze DG. Neurophysiology of Rett syndrome. J Child Neurol. 2005;20(9):740–746. - PubMed
-
- Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol. 2002;6(5):293–297. - PubMed
-
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–188. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 RR000188/RR/NCRR NIH HHS/United States
- NS057819/NS/NINDS NIH HHS/United States
- RR019478/RR/NCRR NIH HHS/United States
- T32 NS043124/NS/NINDS NIH HHS/United States
- K08 NS052240/NS/NINDS NIH HHS/United States
- HD38985/HD/NICHD NIH HHS/United States
- U54 RR019478/RR/NCRR NIH HHS/United States
- P30 HD038985/HD/NICHD NIH HHS/United States
- NS052240/NS/NINDS NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- R01 NS057819/NS/NINDS NIH HHS/United States
- RR00188/RR/NCRR NIH HHS/United States
- NS43124/NS/NINDS NIH HHS/United States
- P01 HD040301/HD/NICHD NIH HHS/United States
- HD40301/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases